| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | CFO and Treasurer
2 companies
Krognes Steve E. is a Director at DNLI, with reported holdings spanning 2 companies. Recent filings cover 0 purchases and 42 sales. Those positions are worth an estimated $1.4M at current prices.
Our model assigns Krognes Steve E. a strong insider score of 74/100, based on 19 past trades. Over a 12-month horizon, 84.2% of those trades were profitable, with an average 12-month return of +27.1%.
Krognes Steve E.'s largest disclosed position is in GH as Director, worth about $1.4M. The recent filings there lean toward selling, a net 15,968 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | GH Guardant Health, Inc. | Director | Sell | 6,674 | $175.74 | $1,172,885.70 | -45.8% | - | - | |
| Jun 4, 2026 | GH Guardant Health, Inc. | Director | Sell | 9,294 | $132.51 | $1,231,521.92 | -47.6% | +22.5% | - | |
| Jan 7, 2025 | DNLI Denali Therapeutics Inc. | Director | Sell | 3,339 | $20.81 | $69,484.59 | -11.5% | -45.2% | -20.0% | |
| Dec 31, 2024 | DNLI Denali Therapeutics Inc. | Director | Sell | 30,000 | $20.25 | $607,500.00 | -50.8% | -33.3% | -19.0% | |
| Sep 30, 2024 | DNLI Denali Therapeutics Inc. | Director | Sell | 30,000 | $29.03 | $870,900.00 | -50.8% | -30.5% | -50.2% | |
| Aug 20, 2024 | DNLI Denali Therapeutics Inc. | Director | Sell | 1,727 | $23.79 | $41,085.33 | -5.0% | +2.2% | -38.6% | |
| Jul 1, 2024 | DNLI Denali Therapeutics Inc. | Director | Sell | 30,688 | $22.11 | $678,659.52 | -47.1% | +32.3% | -36.6% | |
| Apr 1, 2024 | DNLI Denali Therapeutics Inc. | Director | Sell | 92,500 | $20.50 | $1,896,250.00 | -66.1% | +7.1% | -40.2% | |
| Feb 13, 2024 | DNLI Denali Therapeutics Inc. | Director | Sell | 2,750 | $17.29 | $47,547.50 | -1.9% | +13.1% | +22.0% | |
| Jan 5, 2024 | DNLI Denali Therapeutics Inc. | Director | Sell | 3,208 | $19.43 | $62,331.44 | -2.2% | -1.8% | +9.9% |